US Anticoagulation Therapy Market : Increasing prevalence of cardiovascular diseases and blood disorders

The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. The in-office devices segment dominated the US anticoagulation therapy market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services.

What the Market Looks Like?

The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from USD 17.25 Billion in 2016, at a CAGR of 8.5%. The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics.

Market growth is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs)

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575

Objectives of the Study :

  • To define, describe, and forecast the market on the basis of anticoagulation drugs, PT/INR testing devices, and anticoagulation clinics
  • To provide detailed information regarding the major factors influencing growth of the market (drivers, restraints, and industry-specific opportunities)
  • To analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall US anticoagulation therapy industry
  • To forecast the size of the US anticoagulation therapy market
  • To profile key market players in the US anticoagulation market
  • To track and analyze competitive developments such as product launches and approvals in the market

Based on drug type, the anticoagulation therapy market for drugs is segmented into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment dominated the US anticoagulation therapy market for drugs. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs.

The anticoagulation therapy market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. The in-office devices segment dominated the US anticoagulation therapy market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services. However, the home testing devices segment is expected to grow at the highest CAGR due to its advantages such as convenience, time & cost savings, and quick result generation. Additionally, the cost of test devices and the tests themselves are often reimbursable.

Read more about Anticoagulation Therapy Market@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575

The anticoagulation therapy market for clinics is segmented on the basis of type of services and clinics. The types of clinics include hospital associated clinics, independent clinics, and pharmacy-based clinics while the types of services include testing services and consulting services. The pharmacy-based clinics segment is expected to register the highest CAGR during the forecast period. In the US, the number of pharmacy-based anticoagulation clinics has increased significantly in the last few years.